Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Net Margin (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Net Margin data on record, last reported at 13591.0% in Q3 2025.

  • For Q3 2025, Net Margin fell 812713.0% year-over-year to 13591.0%; the TTM value through Sep 2025 reached 9735.75%, down 528625.0%, while the annual FY2024 figure was 6164.4%, 283246.0% down from the prior year.
  • Net Margin reached 13591.0% in Q3 2025 per NWBO's latest filing, down from 12166.41% in the prior quarter.
  • Across five years, Net Margin topped out at 1255.34% in Q1 2023 and bottomed at 15947.57% in Q3 2022.
  • Average Net Margin over 5 years is 6321.77%, with a median of 4984.42% recorded in 2022.
  • Peak YoY movement for Net Margin: skyrocketed 290442356bps in 2021, then tumbled -1220757bps in 2022.
  • A 5-year view of Net Margin shows it stood at 3740.0% in 2021, then decreased by -27bps to 4740.03% in 2022, then soared by 32bps to 3217.53% in 2023, then plummeted by -283bps to 12335.93% in 2024, then fell by -10bps to 13591.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 13591.0% in Q3 2025, 12166.41% in Q2 2025, and 5228.8% in Q1 2025.